No problem. There was decent uptake in Europe which was compelling, this is especially due to the fact that uptake in Europe would have been without a huge marketing campaign, given that the company was clearly waiting for US FDA approval before engaging in a large global marketing campaign. If they could get that sales growth without a huge marketing spend, imagine how well it could do now with a massive all-out global marketing campaign?
Nova Eye Medical (EYE) Discussion, page-960
-
- There are more pages in this discussion • 2,228 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.5¢ |
Change
-0.010(3.64%) |
Mkt cap ! $60.63M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.5¢ | 26.0¢ | $271.6K | 1.011M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1600 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.5¢ | 30180 | 1 |
View Market Depth
| Last trade - 15.55pm 17/07/2024 (20 minute delay) ? |
| EYE (ASX) Chart |